You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Opus Genetics, Inc. and Ashwath Jayagopal agreed that Jayagopal will transition from Chief Scientific and Development Officer effective October 19, 2026 and provide six months of consulting services at $250 per hour; his vested options will remain exercisable during the arrangement.
Opus Genetics expects a $10 million milestone this quarter following FDA approval of a Viatris-partnered presbyopia eye drop, with runway into 2029. Its LCA5 trial is dosing, while another trial enrolled 11 patients.
Opus Genetics reported improved retinal sensitivity in three of four evaluable OPGx-BEST1 participants (75%), sustained OPGx-LCA5 visual improvements through 24 months in adults, and expects Phase 3 OPGx-LCA5 dosing in the fourth quarter of 2026.
